Promising combo tackles relapsed myeloma

NCT ID NCT01615029

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 17, 2026 · Updated 25 times

Summary

This study tested a new combination of drugs (daratumumab, lenalidomide, and dexamethasone) in 45 adults whose multiple myeloma had returned or stopped responding to treatment. The main goal was to check safety and find the right dose, while also measuring how well the drugs shrank the cancer. Results showed many patients had a significant reduction in their cancer, but ongoing treatment is needed to keep the disease under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Study site

Boston, Massachusetts, United States
Study site

Copenhagen Ø, Denmark
Study site

Vejle, Denmark
Study site

Lille, France
Study site

Nantes, France
Study site

Vandœuvre-lès-Nancy, France
Study site

Utrecht, Netherlands
Study site

London, United Kingdom

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA